1 / 38

Post-transplant vaccinations and immune reconstitution

Post-transplant vaccinations and immune reconstitution. Lynne Strasfeld , MD September 13, 2013. A none too infrequent story…. 38 year old man with history of AML, s/p tBuCy MUD PBSCT cGVHD (skin, mouth, eyes) CMV reactivation avascular necrosis of shoulder

chaman
Télécharger la présentation

Post-transplant vaccinations and immune reconstitution

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Post-transplant vaccinations and immune reconstitution Lynne Strasfeld, MD September 13, 2013

  2. A none too infrequent story… • 38 year old man with history of AML, s/p tBuCy MUD PBSCT • cGVHD (skin, mouth, eyes) • CMV reactivation • avascular necrosis of shoulder  off immune suppression as of 9 months post-transplant • Presented 1 year post-transplant with fever, worsening sinusitis…..blood cultures with Streptococcus pneumoniae

  3. Overview • Post-transplant vaccinations • Vaccination schedules & strategies • Immunologic challenges of post-transplant vaccination • Close contacts of transplant recipients • New vaccines

  4. Worldwide, > 50,000 HSCTs performed each year • Vaccine preventable diseases: influenza, pneumococcus, varicella, Bordetellapertussis significant causes of morbidity, re-hospitalization and mortality after successful HSCT • Invasive pneumococcal infections in 590/100,000 allogeneic & 199/100,000 autologous recipients per year, compared with 11.5/100,000 age-matched controls Kumar D, et al. Bone Marrow Transplant 2008. • Lessons from 2009 H1N1

  5. Loss of immunity post-transplant • ~ 50% of patients with positive tetanus & polio titers at the time of allogeneic HSCT will become seronegative at 1 year, with most unprotected against both by 2 years Ljungman P, et al. J Infect Dis1990. • In the absence of revaccination, the majority of allogeneic patients will become susceptible to measles, mumps & rubella by 3-5 years post-HSCT Ljungman P, et al. Bone Marrow Transplant 2009.

  6. Measles • 2001-2010: median 60 cases reported to CDC annually • 2011: 222 cases & 17 outbreaks (including 72 imported cases total 200, or 90%, associated with importation from other countries) • 33/72 (46%) importations were from Europe (*France) & 19/72 (26%) from SE Asia (*India) • 34/46 (74%) were US residents • Most (86%) were unvaccinated or had unknown vaccination status 2 year old boy with recent travel to Pakistan presented to an Oregon hospital with fever & rash, ultimately diagnosed with measles (measles IgM+). Scores of patients/staff exposed in the waiting area/ED. MMWR Morb Mortal Wkly Rep. 2012 Apr;61:253-7.

  7. 1997 measles outbreak in São Paulo: 20,185 cases in 11 months • Seroepidemiologic survey in 156 BMT recipients • 122 NOT vaccinated: 76 were < 2 years post-transplant, 8 on immunosuppression, 38 non-compliant • 41 (34%) susceptible • 43/47 (92%) < 1 year post-transplant were immune, vs. 37/75 (51%) > 1 year post-transplant • Persistence of host-derived humoral immunity for at least 6 months post-transplant • 32/34 vaccinated patients underwent serologic evaluation: 13/32 (41%) susceptible • 16/22 (73%) < 3 years post-vaccination were immune, vs. 3/10 (30%) > 3 years post-vaccination * Significant loss of measles immunity 3 years post-vaccination • 8/54 susceptible patients (IgG<100mIU/mL): attack rate 14.8% • 1 death from measles interstitial pneumonia Machado CM, et al. Blood 2002.

  8. Bordatellapertussis • “whooping cough” • URI symptoms, with protracted cough (“coughing fits”) • In 2012, 910 cases of pertussis reported in Oregon • 4 infant deaths in Oregon since 2003 Oregon Public Health Division, Fact Sheet March 2012

  9. Routine pertussisimmunization begins Reported Pertussis Cases In The US: Then 300 250 200 Cases(Thousands) 150 100 50 0 1922 1930 1940 1950 1960 1970 1980 1990 2000 Year MMWR 2002;51:73-76

  10. And now……. 3.5 week old girl admitted with coughing episodes, admitted April 17th(mother has cough)  apnea, bradycardia, and hypoxia….required ECMO support, with secondary bacterial pneumonia

  11. ???? * 13-valent (PCV-13), 2011 revision † no safety data on the live, cold-adapted vaccine for intranasal administration ‡ serologic testing to determine need for vaccination (CIII) ¤ limited experience with use post-transplant; CII recommendation if >24 months post-transplant, without active GVHD, off immune suppression Ljungman P, et al. Bone Marrow Transplant 2009; CIBMTR - EBMT, CDC, ASBMT, IDSA

  12. Current post-transplant guidelines recommend immunization of all patient groups at fixed time points post-HSCT. • Limited data on efficacy of this approach, particularly for recipients of alternative donors & “atypical” recipients (eg., cord blood, T-cell depleted grafts, reduced intensity regimens, advanced patient age, presence of GVHD and/or recipients of immunomodulatory agents)

  13. Lang PO, et al. J of Aging Research 2012

  14. Delayed recovery of adaptive immunity Bosch M, Khan FM, S J. CurrOpinHematol2012.

  15. Striking delay in recovery of lymphocyte compartment, the “machinery” of the adaptive immune system • Cellular immune response: initiated by antigen presenting cells (eg., dendritic cells) & requires the activation of functional T cells* • Humoral immune response: mediated by antibodies & requires functional B (plasma & memory cells) and T cells* *Functional thymus required for generation of a diverse naïve T cell receptor repertoire

  16. Vaccine variables Host (donor/recipient) variables Age Preexisting immunity (donor* & recipient) Graft type Time post-transplant Immune suppressive regimen (conditioning & immune suppression) Monoclonal antibodies GvHD • Timing • Dosage • Doses • Route (IM, subcutaneous, intradermal) • Conjugate • Pathogen encountered as natural infection (VZV) vs. as vaccination pre-transplant (HBV) vs naïve (pneumococcus) * Vaccination of the donor has been shown to improve recipient post-transplant immunity in the case of tetanus toxoid, PCV7 and H. influenzaetype b-conjugate vaccines.

  17. What are the milestones of immune competence? • 3 doses of IPV (219) & 3 doses of HepB (292) vaccine, if: • CD4 > 200/µl • In vitro T-cell response to phytohemagglutinin(PHA) at least 75% of the lower limit of normal • IgG > 500mg/dL • Off systemic immunosuppressive therapy, minimal/no GVHD Median age 24 (range 0.2-69.0) at time of transplant Vaccinated median 23.4 months post-transplant 65% MRD, 9% MMRD, 25% MUD; 65% T-cell depleted  64% developed protective hepatitis B titers older age & prior chronic GvHDassociated with vaccine nonreponse poorest response in MMRD subset  96% developed a > 4-fold response to all 3 polio serotypes, including recipients of an unrelated and/or T-cell depleted HCT Jaffe D, et al. Blood 2006.

  18. 38 pediatric patients immunized according to the Royal College of Paediatrics and Child Health guidelines for transplant recipients • 3 monthly doses of DTP, IPV & Hib vaccine at • 12 months: autologous (n=10), HLA-matched sib (n=8) • 18 months: unrelated (n=20) • 92% achieved protected titers to all 3 serotypes of polio • 4-fold rise in tetanus titers in 94% • 4-fold rise to H. influenzae titers in 86% (NO in vivo correlates) Patel SR, et al. Clin Infect Dis2007.

  19. 127 HSCT recipients, adults & children (2002-2005) • median age 23, range 0.1-64 • 53% MRD, 5.5% MMRD, 42% MUD; 56% T-cell depleted • Of 53 unmodified HSCTs, 26% developed cGVHD, 32% on IS at time of vaccination •  PCV7 (127) & HIB (115) vaccination • median 1.1 years post-transplant; 81% vaccinated within 2 years 62% (79/127) responded to PCV7: 88% children vs. 44% adults (P<.001) 86% (99/115) responded to HIB: 96% children vs. 79% adults (P=.006) In patients > age 50, 58% (11/19) vaccinated AFTER reaching minimal milestones of immune competence (CD4 > 200/µL, IgG > 500mg/dL, PHA within 60% lower limit normal) responded to PCV7, vs. 0/8 vaccinated prior to milestones (P=.006) Higher numbers of circulating CD4+CD45RA+ T cells improved response to PCV7. Pao M, et al. Biol Blood Marrow Transpl2008.

  20. Influenza vaccination • Influenza vaccination within the first 6 months following HSCT is associated with a poor serologic response to vaccine antigens. Engelhard D, et al. Bone Marrow Transplant 1993. • Addition of GM-CSF to influenza vaccine resulted in a minor improvement in response to influenza B vaccine in HSCT recipients Pauksen K, et al. Clin Infect Dis2000. • In non-transplant patients with hematologic malignancy, 2 doses of influenza vaccine were not more effective than one. Ljungman P, et al. Br J Haematol2005.

  21. CLINICAL EFFICACY of influenza vaccination • 177 transplant recipients (118 allo, 71%) followed for 1 year • 134 were < 6 months post-transplant (unvaccinated)  25 (18.6%) developed influenza • 43 eligible for vaccination (> 6 months post-transplant) • 19 vaccinated: 2/19 (10.5%) developed influenza • 24 unvaccinated: 12/24 (50%) developed influenza • vaccine efficacy 80% (VE¼((r0–r1):r0) Machado CM, et al. Bone Marrow Transplant 2005.

  22. The “over/under approach” to influenza vaccination • No study has reported an increased risk for GVHD in association with influenza vaccination • Data are limited, largely from heterogeneous groups of patients following traditional myeloablative conditioning • Common practice: • Vaccinate yearly, beginning > 4-6 months post-transplant • Consider vaccination between 3-6 months post-transplant, in the context of widespread community activity, with a 2nd dose at 6 months post-transplant • Ensure vaccination of family members/close contacts of transplant recipients & healthcare workers (cocooning)

  23. Influenza vaccine formulations Trivalent vaccines • Inactivated vaccines • IM, all age >6 months • intradermal (licensed in 2011 for ages 18-64, uses 1/5th the usual amount of vaccine antigens) • high-dose vaccine – licensed in 2009 for individuals >65 (based on increased immunogenicity) • Intranasal (LAIV) • master attenuated cold-adapted donor virus from which reassortments are generated with H & N antigens matching circulating strains • approved for ages 2-49 (healthy) • perhaps more effective than inactivated vaccine in children, equivalent in adults • contraindicated:immunocompromised patients, chronic illness (cardiac, pulmonary, DM, renal insufficiency), pregnant women, household members & providers with close contact with severely immunocompromised persons In 2012, the FDA approved a trivalent inactivated influenza vaccine produced in cultured mammalian cells (Flucelvax) for age >18 AND quadrivalent formulations of inactivated and live-attenuated influenza vaccines

  24. Pneumococcal vaccination in SCT recipients • Superiority of conjugate vaccine • 64 donor/recipient pairs, randomized to PPV23 or PCV7 • Pre-transplant vaccination of donor & 6-month post-transplant vaccination of recipient Kumar D, et al. Clin Infect Dis2007. 0% vs 38.6% 55.6% vs 90.9%, P=.02

  25. Pneumococcal vaccination….is earlier better? • 158 patients, 13 EBMT centers •  PCV7 x 3 @ 3 months or 9 months post-transplant • Primary endpoint: antibody level > 0.15µg/mL for each serotype at 1 month after 3rd dose of PCV7 Noninferiority margin 20%  early vaccination: 79%  late vaccination: 82% (P=0.64) • % with positive titers to all 7 serotypes at 24 months post-transplant  early vaccination: 59% • late vaccination: 85% (P=0.013) • cGVHD & older donor age associated with poor response • 2011 update: • PCV13 as replacement for PCV7 Ljungman P, et al. Bone Marrow Transplant 2011. • Prospective open-label study underway WHO threshold for response: >0.35 µg/mL Cordonnier C, et al. Clin Infect Dis2009.

  26. Pneumococcal vaccine updates: “prime – boost” • For patients who have previously received one or more doses of PPSV23, a single dose of PCV13 should be given one or more years after the last PPSV23 dose was received. • For patients who require additional doses of PPSV23, the first such dose should be given no sooner than eight weeks after PCV13 and at least five years after the most recent dose of PPSV23. MMWR October 12, 2012.

  27. Varicella zoster virus Studies of live attenuated varicella vaccine (LAVV) in children post-HSCT Chou JF, et al. Biol Blood Marrow Transplant 2011. Kussmaul SC, et al. Bone Marrow Transplant 2010. Sauerbrei A, et al. Bone Marrow Transplant 1997.  CIBMTR: LAVV can be used in “select patient populations”

  28. Herpes zoster • 20-59% of allogeneic recipients develop shingles within 5 years post-transplant • In 2006, Zostavax® was licensed for prevention of herpes zoster in healthy, immunocompetent adults > 60 • 51.3% fewer episodes of HZ • 66.5% less PHN

  29. Pilot study of Varilrix™ vaccination in 9 VZV-seropositiveautologous HSCT recipients • 3-4 months post-transplant • 2/9 with vesicle formation at injection site • no systemic side effects • “overall strengthening in antigen-specific immune response post-vaccination”, as studied by lymphocyte proliferation (NO statistical difference) • 1/9 developed herpes zoster in follow-up (? 6 months) Ljungman P, et al. Support Care Cancer 2003.

  30. 67 year old man with DLBCL, s/p BuMelT-conditioned autologous SCT 2006, relapse in 2009, on replacement hydrocortisone for adrenal insufficiency • VZV IgG+ pre-transplant • Varivax in March 2010 (with MMR, HepB, and HepA vaccinations) • June 2010  recurrent herpes zoster • November 2010: cutaneous dissemination, pancytopenia with HPS, hepatitis (CD4 53 cells/mm3) • BM & liver biopsy with granulomas, skin biopsy grew VZV (vOka strain) •  multiorgan system failure & death Bhalla P, et al. manuscript in preparation Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol2006.

  31. Heat-inactivated, live attenuated varicella-zoster vaccine • Phase II study • 111 autologous VZV-seropositive HSCT recipients • Vaccinated within 30 days pre-transplant, then at 30, 60, and 90 days post-transplant • Zoster in 7/53 vaccinated (13%) vs 19/58 unvaccinated (33%), P=0.01 • In vitro CD4 T-cell proliferation response to VZV was greater in vaccine recipients & correlated with protection from zoster Hata A, et al. N Engl J Med 2002. • A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs), Merck V212-001 • Vaccination prior to & at 1, 2, and 3 months post-transplant, 1:1 randomization, patients with history of primary varicella and/or VZV IgG+ • 1259 enrolled, 83 confirmed cases of herpes zoster

  32. Vaccines NOT recommended for the transplant recipient • BCG (Bacillus Calmette-Guérin) (live) • Oral poliovirus vaccine (live) • Intranasal influenza vaccine (live) • Cholera • Typhoid, oral (live) • Rotavirus (live, not licensed for adult use) • Zostavax (live) • Yellow fever vaccination contraindicated IF < 24 months, active GVHD, and/or on immunosuppression

  33. DRAFT: OHSU post-transplant vaccination schedule • Recommendations for Autologous and Allogeneic Transplant Recipients* • *Vaccines should be given at indicated time points to all autologous and allogeneic transplant recipients except those with active stage III – IV GvHD; with active infections; or those receiving chemotherapy for relapse, AIHA, etc. • **For recipients who are HepB or HepC positive or those with cGvHD of the liver, NASH, hemochromatosis, or other chronic liver disease, check Hepatitis A antibody titers at 12 months post-transplant. If negative, proceed with Hepatitis A vaccine • £Patient must meet all dosing criteria to receive PPSV23: IgG > 500, CD4 > 200 AND no to minimal immune activation as documented by immune reconstitution panel • §Patient may receive this vaccine if off all immune suppression for at least one year, > 5 months since last IVIG infusion, IgG > 500, CD4 > 200 AND minimal to no immune activation as documented by immune reconstitution panel

  34. What to do with the family? Vaccines to AVOID Vaccines that are okay, but…. Rotavirus vaccine – transplant recipient should avoid changing diapers for 2-4 weeks after vaccination Varivax™ – transplant recipients should avoid vaccinee if a rash develops within 3-6 weeks of vaccination Zostavax™ – transplant recipients should avoid vaccinee if a rash develops within 3-6 weeks of vaccination MMR Yellow fever vaccine • Intranasal influenza vaccine • Oral poliovirus vaccine

  35. New vaccines on the horizon • Heat-inactivated varicella-zoster virus vaccine • CMV vaccine

  36. CMV vaccine study • CMV DNA vaccine (TransVax; Vical) before conditioning and at 1, 3, & 6 months post-transplant • Plasmids encoding glycoprotein B & pp65 • CMV R+ adults @ 16 US transplant centers, NOT T-cell depleted • 94 HSCT recipients & 14 paired donors • Efficacy evaluation in 74 unpaired recipients • 19/40 (48%) of vaccine recipients required CMV-specific antiviral therapy, vs. 21/34 (62%) controls, P = 0.145 Kharfan-Dabaja MA, et al. Lancet Infect Dis2012.

  37. The future • Optimization of post-transplant vaccination algorithms • Parallel assessments of in vitro parameters of immune reconstitution • Prospective study of immunization at fixed time points vs. as guided by immunologic milestones • More, and more effective vaccines

  38. Recent reviews of note • Thom KA, et al. Infection prevention in the cancer center. Clin Infect Dis2013;57:579-585. • Baden LR, et al. Prevention and treatment of cancer-related infections. J NatlComprCancNetw 2012;10:1412-1445.

More Related